IN the Next few weeks there will be leaks as there already are appearing in European medical journals coming out about expanding indications for Sir Spheres therapy with new chemo drugs for other tumor types that have gone to the liver, including breast, pancreas, lung and carcinoid tumors. All these tumor types are having very good responses to Sir Spheres in combination with new chemo drugs. There are no inclusions of any earnings estimates in any of these new indications for Sir Spheres in Sirtex estimates YET. Once backwards analysts realize that there are going to be future earnings from Australian reimbursement, European reimbursement, faster US center growth where 3-5 centers have been added per month more recently and procedures at already existing hospitals is going up alot , and new indications for growth for any tumor that has metastaizes to the liver for which Sir Spheres are designed to treat are also not yet included in earnings estimates, then the conservative 72 cents earnings estimates will be revised alot upwards and the sp will contine a rapid ascent upwards. The backwards analysts who have been recommending gold and oil for the last two years will do a quick about face as well as gold and oil investors ,wont get the picture until the sp is over $4 and they will send it over $5+.THis is just the beginning of the large move and the fuzzy traders will be missing the big move up who daytrade. Here is the heading I found on the internet that low key Sirtex did not yet announce.
Sirtex Provides Educational Grant for Second Annual Symposium on Liver- Directed Microsphere Therapy-Meeting Showcases Latest Research and Treatments for Metastatic Liver Tumors
LAKE FOREST, Ill.,Sirtex, a leading developer of targeted and innovative cancer therapies, is providing an educational grant to support the second annual symposium on Liver-Directed Microsphere Therapy April 27-28 , 2006 at the Westin Kierland Resort and Spa in Scottsdale, Ariz. The symposium is jointly sponsored by Wake Radiology Oncology Services in Cary, N.C., and Medical Education Collaborative based in Golden, Colo. It will serve as a clinical exchange forum and feature the latest clinical data on microsphere therapy for treating advanced liver cancer. Sirtex's SIR- Spheres(R) microspheres are the only FDA approved radioactive microspheres for treatment of metastatic liver tumors.
"This year's symposium will feature the world's leading clinical experts on radioactive microsphere therapy," says Dr. Andrew Kennedy, radiation oncologist and co-medical director of Wake Radiology Oncology. "It is exciting to see the growing amount of clinical research and published articles on microsphere therapy. A lot of new data will be presented at the symposium, expanding our knowledge of microsphere therapy and our ability to treat advanced liver tumors."
Sirtex's educational grant illustrates the company's ongoing commitment to educating physicians and patients on the latest microsphere therapies. Sirtex's SIR-Spheres microspheres are radioactive polymer spheres that emit beta radiation. Physicians insert a catheter through the groin into the hepatic artery and deliver millions of SIR-Spheres microspheres directly to the tumor site. The SIR-Spheres microspheres target the liver tumors, sparing healthy liver tissue. The minimally invasive procedure is performed on an out- patient basis with minor side effects. Clinical research shows that use of SIR-Spheres microspheres increases patient survival rates by an average five to six months.
"Sirtex is excited to once again be part of such an important meeting," says Charles Rowland, president of Sirtex Medical, Inc. "We feel it is important to get the latest data into the hands of physicians who treat liver cancer patients and who continue to try to improve the lives of people with liver cancer."
Symposium sessions will include the latest clinical data on microsphere therapy for advanced metastatic colorectal cancer, breast cancer, carcinoid tumors and other metastatic liver disease. For more information on the symposium, please visit http://www.wakeradiologyoncology.com . Members of the media interested in attending the symposium may contact Andrea Moody at 919-457-0743 or [email protected] .
About Sirtex
SIR-Spheres microspheres were developed in the 1980s in Australia and were approved by the FDA in March 2002. Sirtex has obtained regulatory approval to market SIR-Spheres microspheres in the United States, European Union, Israel and Australia. The product is marketed in New Zealand, Hong Kong, Malaysia, Singapore and Thailand. For more information, visit http://www.sirtex.com .
SIR-Spheres is a registered Trademark of Sirtex Medical Limited.
SOURCE Sirtex
CONTACT: Andrea Moody, for Sirtex, +1-919-457-0743, [email protected]
URL: http://www.prnewswire.com
http://www.wakeradiologyoncology.com
http://www.sirtex.com www.prnewswire.com
Copyright (C) 2006 PR Newswire. All Rights Reserved.
Contact Us | Terms & Conditions | Privacy Policy | HIPAA Privacy Notice No duplication of any material herein is authorized without the express consent of Apria Healthcare, Inc. Please review the Terms and Conditions of this Web site.
SRX Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
(20min delay)